Center of excellence for the development and manufacture of specialized drug products based on liquid-filled hard capsule (LFHC) technology
Our Edinburgh facility is one of the world's largest dedicated sites for the design, development and manufacture of liquid and semi-solid pharmaceutical products using liquid-filled hard capsule (LFHC) technology. The site is fully integrated and supports all aspects of product and process development, scale-up and manufacture of LFHC products. The Lonza Edinburgh team has over 25 years’ experience in developing and commercializing these innovative products using LFHC technology and specialized production techniques.
LFHC technology is utilized to address a number of formulation challenges including:
- Poorly soluble compounds using lipid / solvent / co-solvent based formulations
- Safe handling and consistent dosing for highly potent / low dose applications
- Targeted delivery to the colon
- Abuse deterrent formulations
LFHC technology also offers a rapid formulation tool for first-in-human studies and is an integral part of our SimpliFiH™ Solutions package. LFHC formulations are typically used for solubility and food effect challenges associated with highly lipophilic compounds.
Pharmaceutical LFHC products are also developed and manufactured at our Ploermel France location. Additional LFHC development and production sites for the consumer health & nutrition markets are located in Colmar (France) Greenwood (US) and Sagamihara (Japan). Best practices related to product development and process development, capsule filling and sealing, and scale-up are routinely shared within our LFHC network.